EnantiopureC1-Symmetric Bis(imino)pyridine Cobalt Complexes for Asymmetric Alkene Hydrogenation
摘要:
Enantiopure C-1-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.
EnantiopureC1-Symmetric Bis(imino)pyridine Cobalt Complexes for Asymmetric Alkene Hydrogenation
摘要:
Enantiopure C-1-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.
Iridium-Catalyzed Asymmetric Transfer Hydrogenation of 1-Aryl-1-alkylethenes with Ethanol
作者:Xixia Tang、Lu Qian、Guixia Liu、Zheng Huang
DOI:10.1021/acs.orglett.3c01880
日期:2023.7.7
Asymmetric transfer hydrogenation of 1-aryl-1-alkylethenes with ethanol was developed with a chiral (PCN)Ir complex as the precatalyst, featuring high enantioselectivities, good functional group tolerance, and operational simplicity. The method is further applied to formal intramolecular asymmetric transfer hydrogenation of alkenols without an external H-donor, producing a tertiary stereocenter and
以手性(PCN)Ir配合物为预催化剂,开发了1-芳基-1-烷基乙烯与乙醇的不对称转移氢化反应,具有对映选择性高、官能团耐受性好、操作简单等特点。该方法进一步应用于无需外部氢供体的烯醇的正式分子内不对称转移氢化,同时产生叔立构中心和远程酮基。克级合成和( R )-黄根醇关键前体的合成凸显了催化系统的实用性。
PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP3252049A1
公开(公告)日:2017-12-06
The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
本发明提供了式 (I) 的化合物:
或其立体异构体、同系物或药学上可接受的盐,其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
Enantiopure<i>C</i><sub>1</sub>-Symmetric Bis(imino)pyridine Cobalt Complexes for Asymmetric Alkene Hydrogenation
作者:Sebastien Monfette、Zoë R. Turner、Scott P. Semproni、Paul J. Chirik
DOI:10.1021/ja300503k
日期:2012.3.14
Enantiopure C-1-symmetric bis(imino)pyridine cobalt chloride, methyl, hydride, and cyclometalated complexes have been synthesized and characterized. These complexes are active as catalysts for the enantioselective hydrogenation of geminal-disubstituted olefins.